Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alfa-2b

Acta Haematologica

Volumn 130, Issue 1, 2013, Pages 44-46

  Zhang, Xueya ^a   Pan, Jingxin ^a   Guo, Jianxin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic neutrophilic leukemia; Interferon alfa 2b; JAK2 V617F

Indexed keywords

ALPHA2B INTERFERON; C REACTIVE PROTEIN; HEMOGLOBIN; JAK2 V617F PROTEIN; JANUS KINASE 2; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC NEUTROPHILIC LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; DYSPLASIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; KARYOTYPE 46,XY; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MIDDLE AGED; MYELOBLAST; NEUTROPHIL COUNT; PATIENT REFERRAL; PRIORITY JOURNAL; RARE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; TREATMENT DURATION; TREPHINE; ULTRASOUND;

EID: 84873391996     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000345851     Document Type: Article

References (7)

1. Elliott MA, Dewald GW, Tefferi A, Hanson CA: Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia 2001; 15: 35-40.
2. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A: WHO-defined chronic neutrophilia leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia 2005; 19: 313-317.
3. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gary Gilliland D, Tefferi A: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207-1209.
4. Mc Lornan DP, Percy MJ, Jones AV, Cross NC, Mc Mullin MF: Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica 2005; 90: 1696-1697.
5. Lea NC, Lim Z, Westwood NB, Arno MJ, Gaken J, Mohamedali A, Mufti GJ: Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukemia. Leukemia 2006; 20: 1324-1326.
6. Kako S, Kanda Y, Sato T, Goyama S, Noda N, Shoda E, Oshima K, Inoue M, Izutsu K, Watanabe T, Motokura T, Chiba S, Fukayama M, Kurokawa M: Early relapse of JAK2 V617Fpositive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol 2007; 82: 386-390.
7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.